Medtronic - MDT STOCK NEWS

Medtronic announced early data from its Intrepid transcatheter mitral valve replacement (TMVR) system at the TCT conference following FDA IDE approval for transfemoral access in the APOLLO trial. Early results show 100% survival and no strokes among the first 15 patients, with a median procedure time of 46 minutes and trace mitral regurgitation in all patients at 30 days. This delivery method may reduce procedural risks. The Intrepid system has been employed in over 350 patients globally, indicating significant interest in its potential for wider clinical use.

Medtronic (NYSE:MDT) announced positive five-year clinical results from the SURTAVI Trial for TAVR patients at intermediate risk. The trial revealed that TAVR with the CoreValve and Evolut platforms demonstrated comparable all-cause mortality rates (30.0% for TAVR vs. 28.7% for SAVR) and lower mean aortic valve gradients (8.6 mm Hg vs. 11.2 mm Hg), ensuring valve performance and safety. The study included 864 TAVR patients compared to 796 surgical patients, highlighting the long-term viability of TAVR in treating severe aortic stenosis.

Medtronic has presented findings from a Patient Preferences study on hypertension treatment at TCT 2021, revealing that patients are willing to accept interventions even with modest blood pressure reductions. The study showed that 76.5% would consider renal denervation (RDN) for a 10 mmHg decrease. Additionally, Medtronic launched the SPYRAL AFFIRM study, focusing on the safety and efficacy of RDN in patients with uncontrolled hypertension and comorbidities. The study will enroll 1,000 patients over three years and is part of a broader effort to establish RDN as a viable treatment option.

Medtronic plc (NYSE: MDT) and Rune Labs have announced a collaboration aimed at enhancing patient care through neurostimulation data analysis. The project will utilize Rune's software to integrate and analyze data from Medtronic's Percept™ PC Neurostimulator and the StrivePD Apple Watch app, focusing on Parkinson's disease treatment. This innovative approach will enable continuous monitoring of local field potentials, potentially guiding personalized treatment decisions. The initiative includes a 12-month monitoring plan for up to 1,000 patients across selected DBS centers.

Medtronic plc (NYSE:MDT) has appointed Dr. Austin L. Chiang as the Chief Medical Officer (CMO) for its Gastrointestinal (GI) business. Dr. Chiang, an accomplished gastroenterologist, will offer strategic guidance on clinical communications, risk management, and patient safety throughout the product lifecycle. His expertise includes advanced endoscopy and obesity medicine, enhancing Medtronic's innovation in GI care. Dr. Chiang will continue his clinical practice at Jefferson Health while contributing to product development and clinical trials at Medtronic.

Medtronic (NYSE: MDT) reported promising results from a study involving 3,211 pediatric patients with type 1 diabetes using the MiniMed™ 780G system. The one-year data revealed a 74% average Time in Range and 82% overnight Time in Range, outperforming clinical guidelines. The study demonstrated that 75.3% of users achieved a Glucose Management Indicator (GMI) below 7%. The MiniMed 780G system’s advanced hybrid closed-loop algorithm adapts insulin delivery every five minutes, leading to improved glycemic control and personalization, making it an effective choice for managing diabetes in children.

Medtronic has announced the receipt of CE Mark for its Hugo™ robotic-assisted surgery system, enabling its sale in Europe for urologic and gynecologic procedures. This approval is significant as robotic surgery currently represents only 3% of global surgeries, despite its benefits like reduced complications and shorter hospital stays. With strong interest from European hospitals, Medtronic plans swift installations, aiming to enhance access to robotic-assisted surgery. The Hugo system emphasizes affordability and utilization, addressing historical barriers to adoption.

Medtronic plc (NYSE: MDT) published a study revealing a significant link between atrial fibrillation (AF) episodes and ischemic stroke risk. Conducted using continuous rhythm monitoring devices on 891 patients with cardiovascular implants, the study found that 16% had AF lasting over 5.5 hours, increasing 30-day stroke risk over three-fold. The findings, published in JAMA Cardiology, suggest that time-limited anticoagulation may be effective in stroke prevention following AF episodes. The study emphasizes the need for continuous monitoring to identify high-risk patients.